AVXL (Anavex Life Sciences) Total Assets: $132.99 Mil (As of Dec. 2025)


AVXL Anavex Life Sciences Corp AVXL
30 GF Score
Price $2.59
! 1 Warning Sign
View Full Analysis

What is Anavex Life Sciences Total Assets?

Anavex Life Sciences AVXL -0.19% 30 Total Assets is $132.99 Mil as of Dec. 2025. GuruFocus rates AVXL with a GF Score™ of 30/100. The stock has 1 warning sign investors should review.

Anavex Life Sciences's Total Assets for the quarter that ended in Dec. 2025 was $132.99 Mil.

During the past 12 months, Anavex Life Sciences's average Total Assets Growth Rate was -63.40% per year. During the past 3 years, the average Total Assets Growth Rate was -29.60% per year. During the past 5 years, the average Total Assets Growth Rate was -25.80% per year. During the past 10 years, the average Total Assets Growth Rate was 27.70% per year.

During the past 13 years, Anavex Life Sciences's highest 3-Year average Total Assets Growth Rate was 347.30%. The lowest was -67.50%. And the median was 42.70%.

Total Assets is connected with ROA %. Anavex Life Sciences's annualized ROA % for the quarter that ended in Dec. 2025 was -19.19%. Total Assets is also linked to Revenue through Asset Turnover. Anavex Life Sciences's Asset Turnover for the quarter that ended in Dec. 2025 was 0.00.

Anavex Life Sciences  (NAS:AVXL) Total Assets Explanation

Total Assets is connected with ROA %.

Anavex Life Sciences's annualized ROA % for the quarter that ended in Dec. 2025 is

ROA %=Net Income (Q: Dec. 2025 )/( (Total Assets (Q: Sep. 2025 )+Total Assets (Q: Dec. 2025 ))/ count )
=-22.724/( (103.815+132.989)/ 2 )
=-22.724/118.402
=-19.19 %

Note: The Net Income data used here is four times the quarterly (Dec. 2025) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Anavex Life Sciences's Asset Turnover for the quarter that ended in Dec. 2025 is

Asset Turnover
=Revenue (Q: Dec. 2025 )/( (Total Assets (Q: Sep. 2025 )+Total Assets (Q: Dec. 2025 ))/ count )
=0/( (103.815+132.989)/ 2 )
=0/118.402
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Anavex Life Sciences Total Assets Related Terms

Anavex Life Sciences Total Assets Historical Data

* Premium members only.

The historical data trend for Anavex Life Sciences's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Anavex Life Sciences Total Assets Chart

Anavex Life Sciences Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
Total Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 161.62 152.71 154.39 135.57 103.82

Anavex Life Sciences Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Total Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 124.04 117.14 102.43 103.82 132.99
AVXL
30GF Score
Anavex Life Sciences Corp AVXL
Total Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Anavex Life Sciences Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Anavex Life Sciences's Total Assets for the fiscal year that ended in Sep. 2025 is calculated as

Total Assets=Total Equity (A: Sep. 2025 )+Total Liabilities (A: Sep. 2025 )
=94.869+8.946
=103.82

Anavex Life Sciences's Total Assets for the quarter that ended in Dec. 2025 is calculated as

Total Assets=Total Equity (Q: Dec. 2025 )+Total Liabilities (Q: Dec. 2025 )
=126.618+6.371
=132.99

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Assets →
What does a Total Assets of $132.99 Mil mean?
Anavex Life Sciences (AVXL) has a Total Assets of $132.99 Mil as of Dec. 2025. The total amount of assets as recorded on a company's balance sheet. View historical data on Anavex Life Sciences and its competitors.
Is Anavex Life Sciences' Total Assets too high?
Anavex Life Sciences' current Total Assets is $132.99 Mil. Overall, Anavex Life Sciences has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Anavex Life Sciences' Total Assets compare to SLGL and FATE?
Anavex Life Sciences' Total Assets of $132.99 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Biotechnology company?
A good Total Assets depends on the Biotechnology industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on Anavex Life Sciences and its competitors. Anavex Life Sciences's current Total Assets is $132.99 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anavex Life Sciences stock overvalued right now?
Anavex Life Sciences (AVXL) has a current Total Assets of $132.99 Mil. The current Total Assets is $132.99 Mil. Anavex Life Sciences' overall GF Score™ is 30/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For Anavex Life Sciences (AVXL), the current Total Assets is $132.99 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Anavex Life Sciences Business Description

Other Exchanges 0HFR:UK12X1:Germany
Address 630 5th Avenue, 20th Floor, New York, NY, USA, 10111
Anavex Life Sciences Corp is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system(CNS) diseases with high unmet need. It analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. The company focuses on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its pipeline includes ANAVEX 2-73 and ANAVEX 3-71 and several other compounds in different stages of clinical and pre-clinical development.
30GF Score

Get the complete analysis for AVXL

Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.59
Price